AIDP Granted U.S. Patent for Cognitive-Health Ingredient Magtein

August 20, 2012

The patents cover Magtein's magnesium composition and uses for cognitive function and neurological disorders.

AIDP Inc. (City of Industry, CA) has gained two U.S. patents for Magtein magnesium L-threonate, which the company calls the “next breakthrough ingredient for cognitive health.” The patents cover magnesium compositions and uses for cognitive function (Patent 8,178,118) and neurological disorders (Patent 8,142,803).

AIDP says the two new patents are among the four U.S. patents awarded from seven ongoing patent applications, including international rights. The patents protect Magtein’s unique magnesium compositions and its use for any magnesium L-threonate-containing food, nutritional supplements, and drugs for enhancing cognitive function or ameliorating the effects of a neurological disorder.

The company says uses include improving the health of people suffering from loss of cognitive function, loss of memory, Alzheimer’s disease, depression, attention deficit hyperactivity disorder, and mood disorder, among others.

Magtein, whose published studies include those in Neuron (January 2010) and The Journal of Neuroscience (October 2011), is said to be the only form of magnesium proven to significantly improve brain magnesium levels, says AIDP. The company also says that animal research has shown Magtein to improve short-term and long-term memory, as well as spatial recognition.